Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.57 |
| ▸ | ITGAV | P06756 | 3/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016235 | 1.00 | ITGB3 (0.57) | ITGB3ITGAVITGA2BALDH1A1MEN1 | |
| SCHEMBL6016141 | 0.82 | ITGB3 (0.56) | ITGB3ITGAVITGA2BALDH1A1MEN1 | |
| SCHEMBL6016195 | 0.81 | ITGB3 (0.46) | ITGB3ITGAVITGA2BALDH1A1 | |
| SCHEMBL6016196 | 0.81 | ITGB3 (0.46) | ITGB3ITGAVITGA2BALDH1A1 | |
| SCHEMBL6016274 | 0.81 | ITGB3 (0.57) | ITGB3ITGAVITGA2BALDH1A1MEN1 | |
| SCHEMBL3892302 | 0.76 | ALDH1A1 (0.51) | ITGB3ITGAVITGA2BALDH1A1MEN1 | |
| SCHEMBL6016302 | 0.73 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL6016304 | 0.73 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL6016151 | 0.72 | ITGB3 (0.84) | ITGB3ITGAVITGA2B | |
| SCHEMBL6016258 | 0.72 | ITGB3 (0.84) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1086098-B1 | THIENYL SUBSTITUTED ACYLGUANIDINES AS INHIBITORS OF BONE RESORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA GMBH (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-6660728-B2 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-09 | — | — | US | disclosed |
| US-20030153557-A1 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH AND GENENTECH, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6566366-B1 | For therapy of tumor growth, osteoporosis, inflammation and cardiovascular disorders | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-20 | — | — | US | disclosed |
| EP-1086098-A1 | THIENYL SUBSTITUTED ACYLGUANIDINES AS INHIBITORS OF BONE RESORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS | Aventis Pharma Deutschland GmbH (DE) | 2001-03-28 | — | — | EP | disclosed |
| EP-0960882-A1 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-12-01 | — | — | EP | disclosed |
| WO-1999059992-A1 | THIENYL SUBSTITUTED ACYLGUANIDINES AS INHIBITORS OF BONE RESORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153557-A1 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | ASGR1, PTMS, B3GNT2 | ITGB3 250/4885ITGAV 376/4885ITGA2B 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.